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Sickle cell disease (SCD) is a chronic illness, and the major complication, pain, results in complex multidimensional problems
that aﬀect an individual’s ability to maintain adequate quality of life in multiple areas. Chronic SCD pain is inadequately treated,
because it is not well understood, and the degree of chronic pain, clinical presentation, and sequela complications can vary from
patient to patient, even among individuals with the same SCD genotype. The reason for this variation is unknown, but the
underlying cause might be genetic. Researchers have not explored the contribution of a genomic variable to the occurrence of
heterogeneous chronic SCD pain. Previous research on the guanosine triphosphate cyclohydrolase (GCH1) gene suggests that in
some cases, phenotypic heterogeneity in human sensitivity to pain correlates with underlying genotypic variations in the GCH1
gene. These ﬁndings imply that genotypic variations might also explain why some SCD patients experience more chronic pain
than others.
1.Introduction
The chronic pain in sickle cell disease (SCD) is a com-
plex, distressing, and multidimensional problem that has
no satisfactory therapy and needs more focused research.
Patients suﬀering from SCD frequently complain of chronic,
debilitating pain, yet, the degree of that pain varies from
patient to patient, even among individuals with the same
genotype. With patient-to-patient variation (heterogeneity)
of pain, one might ponder: do genes inﬂuence how much
chronic pain variability individuals with SCD experience?
There is an evolving body of literature that provides
evidence that chronic pain experiences in other diseases or
conditions are associated with genetic inﬂuences of pain
genes[1–6].EventhoughSCDisageneticdisorder,theeﬀect
of genomics on the presence of chronic pain in SCD has
not been examined. By incorporating molecular genetic pain
ﬁndings into research on pain experiences in SCD, emerging
informationmayhelptoexplaintheheterogeneityofchronic
pain ratings among those with SCD and other chronic pain
syndromes. With signiﬁcant discoveries of how genes and
allelic variations can modulate pain sensitivity and variation
among individuals [1–6], it may become routine practice in
the future to screen individuals with chronic pain for genetic
susceptibility, and hence provide personalized care [7]a n d
treatment relative to an individual’s genetic predisposition.
The purpose of this paper is to introduce researchers and
practitioners to current ﬁndings about a candidate gene’s
contribution to pain and to highlight the need to include a
genomic variable when evaluating chronic pain in individu-
als with SCD. Since evidence shows that pain genetics play
an important part in chronic pain trajectory [1–6], inclusion
of genomic information could impact the identiﬁcation of
susceptibility to chronic pain, management strategies, care
outcomes, and overall quality of life of individuals. A better
understanding of the major complications of SCD, chronic
pain, and the genomic eﬀect of pain-protective genes may
help to explain heterogeneity of chronic pain occurrences
and why the experiences of pain vary from patient to patient.
2.Background
2.1. Sickle Cell Disease. SCD is a single-gene disorder result-
ing from point mutation and deoxyribonucleic acid (DNA)
malfunction in which a single base pair in the nucleotide is
aﬀected. At the cellular level, on codon 6 of the hemoglobin2 ISRN Nursing
gene, glutamic acid is replaced by valine because of the
chromosomal defect. The result of this genetic mutation is
protein change, multisystem defects, and pain [8, 9].
2.1.1. Epidemiology. SCD aﬀects over 70,000 to 100,000
individuals in the US [10, 11] and approximately 300,000
infants who are born annually throughout the world, with
most of these infant births being in developing countries
in Africa [12]. SCD mainly aﬀects individuals of African,
especially sub-Saharan, descent and occurs in approximately
one out of every 500 births among African Americans
and one out of 1,400 births among Hispanic Americans
[13]. Hispanic Americans are part of the emerging SCD
population. With easy and rapid global transcultural travel,
and an admixture of individuals from varying ethnicities,
SCD prevalence will increase.[12, 14, 15]. Hence, SCD
aﬀects many individuals worldwide who were not originally
included in the disease susceptibility forecast and is a global
public health concern [16]. Those aﬀected by SCD are faced
with multisystem, multidimensional problems that impinge
on every domain of human life and include biophysical,
sociological, psychosocial, and spiritual malfunctions.
2.2. Chronic Pain. Chronic pain is a disease unto itself [17]
and a serious public health problem that is associated with
increased risk of death [18]. With recognition that chronic
pain is a disease consisting of a constellation of signs and
symptoms, providers are called to diagnose and treat the
condition and the intense accompanying complications that
causefurtherhealthproblems.Chronicpainresultsinpersis-
tent discomfort and inadequate care for individual suﬀerers.
[19].Accompanyingchronicpainaresequelaconditions that
can lead to psychological changes such as sleep disturbances
[20, 21] and psychopathology such as depression, anxiety
and personality disorders [22, 23], brain damage, altered
neurochemistry,andatrophy[17],whichmaybeirreversible.
Unrelieved pain aﬀects social lives, results in pecuniary
burdens[24]andsocialandpsychologicallosses[24–27]and
places economic burdens on society [28].
In general, the deﬁnition of chronic pain remains
nebulous and temporal. The International Association for
the Study of Pain [29] and American Pain Society [30]r e f e r
to chronic pain as pain occurring beyond normal tissue
healing time, 3 months. Unlike acute pain, chronic pain
serves no known adaptive purpose [31], may reﬂect ongoing
tissue damage [28, 32, 33] including brain damage [17], and
often leads to a burdensome life path [28].
Providers widely view chronic pain as a multifaceted,
biopsychosocial, and spiritual phenomenon that can be
associated with psychopathology [14] and which is best
managed using a holistic, multidisciplinary approach [22].
Individuals with chronic pain should be treated early and
aggressively to minimize altered brain physiology, poor
memory, and other complications [17].
2.2.1. Chronic Pain with SCD. Chronic pain, in general, is
inadequatelydeﬁned,andSCD-relatedchronicpainispoorly
characterized and sparsely researched [33, 34]. Chronic
aching pain, the hallmark and deﬁning feature of SCD,
occurs in addition to periodic acute pain. The chronic pain
varies in intensity and duration and is considered to be
unrelenting and crippling [35, 36].
Individuals with SCD are primarily of minority eth-
nicities. Their reports of pain are often underestimated
a n du n d e r t r e a t e d[ 30], and they are at risk for inadequate
treatment within existing healthcare systems [37, 38]. The
chronic pain is often managed on an outpatient basis with
analgesics and adjuvant therapy, but both patients and
healthcare providers express concerns about inadequate pain
management [37, 38]. Moreover, clinicians and researchers
do not agree on chronic pain deﬁnition, classiﬁcation, or
appropriate management strategies that actually meet the
needs of individuals with SCD.
Chronic pain, the major presenting symptom of SCD,
is complex, poorly understood, and the leading reason
for hospitalizations and emergency department visits [39].
The pain is unrelenting, unpredictable, and diﬀerent for
each individual [40]. Daily experiences diﬀer from prior
experiences and become the focus throughout the indi-
vidual’s life, thus negatively aﬀecting one’s quality of life
(QOL) [41, 42]. Recent research suggests that patients with
S C Dh a v em o r ep a i nt h a nw a sp r e v i o u s l yr e p o r t e d ,h a v e
constant pain most days, self-manage the pain at home,
and report increased pain despite opioids for analgesia. The
pain often intensiﬁes and necessitates healthcare utilization
such as emergency room visits [39, 42]. The pain, at times,
reﬂects a combination of chronic pain as a basal event with
superimposed escalations of acute pain. Hence, the pain
may be similar in type, location, or quality to usual chronic
pain, but the severity is increased [43]. Individuals with SCD
report experiential knowledge of being able to distinguish
the pain type and can diﬀerentiate pain related to chronic
everyday SCD pain from nonsickle cell disease-related pain
and from chronic pain with increased acute intensity or
exacerbation [44].
Published guidelines for the Management for Sickle Cell
Disease identify chronic pain as a unique syndrome that
occurs after approximately 3-to-6 months [30] after injury.
In this guide, however, there is no oﬀered explanation for the
heterogeneity (patient-to-patient variation) of chronic pain
experiencethatoccursevenamongindividualswiththesame
sickle cell genotype. For individuals with SCD, the generic
deﬁnition of chronic pain that has been used is the same
for other disease processes and events and is unclear. The
temporal presentation and nomenclature of chronic pain in
individuals with SCD does not aptly ﬁt this generic chronic
pain description and possibly needs to be revisited and in
the future clariﬁed. Varying presentations such as frequency,
intensity, and duration of chronic pain of SCD genotype
need to be clariﬁed and deﬁned from the perspective of
an individual with the illness. This, combined with genetic
studies, might reveal some clues about genes that inﬂuence
SCD chronic pain.
2.3. Genomics and Pain. Even though the pain phenotype
represents a subjective perception and is often diﬃcult to
measure, there is a need for more quantitative data on
chronic pain phenotypes and genomic predisposition. TheISRN Nursing 3
molecular epidemiologic mechanism of pain can better
explain the phenotype. Since pain is no longer attributed
solely to neurophysiologic changes, the study of pain must
include genomic inquiry [45], which should include genetic
contribution to pain itself, pain as a disease, and genetic
factors playing a role in variability of pain experiences.
Evolving information on pain protective genes has impli-
cated genetic predisposition to chronic pain. With such
emergingdiscoveriesonpaingenetics,clinicalpracticemight
have better or more poignant tools to help direct and
predict care of those with chronic pain. This burgeoning
body of pain genetic research suggests that variability in
the gene loci contributes to individual experiences in pain
sensitivity [46, 47]. Even in multifactorial pain syndromes,
there is substantial heritability [1–6]. Two major approaches
to conducting pain genetics research are genome wide
association studies (GWAS) and cadidte gene studies where
speciﬁc mutations (polymorphisms or single nucleotide
polymorphisms [SNPs]) in candidate genes have already
been identiﬁed. The candidate gene approach is hypothesis
driven and targeted to speciﬁc pre-examined SNPs. Con-
versely GWAS are not hypothesis driven and tend to be
untargeted and spread across the whole genome [48].
Pain genetics research helps to explain chronic pain
mechanismsandgenomicvariabilityinindividuals’suscepti-
bility to chronic pain disorders. Genetic variables associated
with chronic pain may help to clarify pathophysiologic
mechanisms and help to identify patients who are at risk for
developing chronic pain and other complications [49]. The
long-term promissory outcome includes personalization of
pain treatment in response to individual genomic structure.
2.3.1. A Pain Protective Gene: GCH1. In order to understand
the potential value of examining the relationship of genetics
with SCD, examining the research related to guanosine
triphosphate cyclohydrolase (GCHI) gene can provide some
beginning insight. Emerging genetic research has identiﬁed
single nucleotide polymorphism (SNP) variations (muta-
tions) in pain protective genes that contribute to protection
orminimizationagainstchronicpain[50–53]andindividual
diﬀerences in pain sensitivity. These relationships have not
been examined in African Americans (AA) or in those with
SCD and may contribute to understanding of this complex
condition.
Recent studies suggest that polymorphisms in the
guanosine triphosphate cyclohydrolase (GTP cyclohydrolase)
(GCH1) gene within chromosome 14Q22-Q22.2 provide
pain protection [52, 53]. SNPs in GCH1 (rs8007267,
rs3783641, and rs10483639) have been associated with
reduced tetrahudrobiopterin (BH4) levels and reduced pain
sensitivity among adults with chronic pain. [50, 54] Individ-
uals with GCH1 gene variant (expressed uncommon alleles)
have less chronic pain.
The GCH1 pain protective haplotype has been associated
with lower pain ratings in healthy volunteers in four
independent studies [50–52, 55] and in individuals with
chronic pain in two studies [52, 55]. In the Tegeder et al. [52]
study,theresearchersreportedthatspeciﬁcgeneticvariations
in the GCH1 gene were associated with reduced severity
of persistent leg pain among 168 Caucasians with chronic,
persistent lumbar root pain who underwent diskectomy.
In this study, individuals were genotyped for 15 SNPs
in the GCH1 gene. One year after surgery, 147 subjects
completed the followup questionnaire, and among them, 5
SNPs in GCH1 were signiﬁcantly associated with increased
scores of persistent leg pain, which was the pre-speciﬁed
primary outcome. Hence, GCH1 was shown to have a
single haplotype. A single haplotype or haplotype block is a
sequence of contigious SNPs in the DNA that are statistically
associated [56]. The researchers also evaluated experimental
pain sensitivity in two separate cohorts of healthy volunteers.
Thosehomozygousforthishaplotypeexhibitedreducedpain
sensitivity to experimental pain compared to controls.
Additionally, Tegeder et al. [51] showed a haplotype
block is associated with pain protection and, in normal
volunteers, lower ratings of experimental pain stimuli. The
aim of the study was to provide further evidence for pain
protectiveeﬀectoftheGCH1haplotype.Thisstudyconsisted
of 11 homozygous carriers of the GCH1 haplotype who were
previously identiﬁed in an earlier study and 23 noncarrier
controls who were matched by age and gender. The study
was double blind in regard to participants’ GCH1 genotype.
The healthy volunteers were rated for sensitivity to pain from
injury to the skin or capsaicin-evoked primary hyperalgesia.
This veriﬁcatory study had small, but acceptable, sample
sizes and revealed that compared to controls, carriers GCH1
upregulation was lower in carriers of GCH1 haplotype than
in noncarriers. Subsequently, L¨ otsch et al. [57] reexamined
the pain haplotype of 15 DNA positions of the GCH1 gene
[52] and concluded that there was 100% sensitivity and
speciﬁcity by screening forjust3GCH1 genevariantsinstead
of the originally stated 15. The 3 GCH1 SNPs that span the
entire DNA range of the haplotype are rs 8007267 G > Ai n
the 5-untranslated region, rs3783641A > T in intron 1, and
rs10483639C > G in the 3 untranslated region [57].
Recently, Campbell et al. [50] also concluded that the
GCH1 polymorphisms were associated with lower pain
ratings in a group of healthy human volunteers who received
inducedpainfulstimuli.Inthisstudyof39healthyvolunteers
who participated in a neuroimaging PET study, individuals
were genotyped and topical capsaicin cream was applied to
the dorsal aspect of hand. Pain ratings were collected over
a 90 minute interval. By using analysis of covariance, the
researchers correlated the relationships between 5 SNPs and
mean rating of experimental capsaicin pain. The individuals
with the uncommon alleles reported 44% less pain than
noncarriers.
In veriﬁcatory studies, Doehring and colleagues [55]
conducted an observational cross-sectional analysis among
Caucasian volunteers and concurred that the GCH1 pain
protective eﬀect is associated with the GCH1 haplotype.
The study involved 523 patients who were enrolled in three
diﬀerent outpatient pain centers and had therapy for less
than a month. Data were analyzed on 424 of 519 self-
reported Caucasians participants. Both genotype and pain
phenotype data were collected. The results indicate that
lowerlevelsofGCH1expressionhaveapainprotectiveeﬀect.
This decreased GCH1 upregulation may be prophylactic and4 ISRN Nursing
delay the need for pain therapy. Patients with this haplotype
needed shorter therapy than noncarriers [55].
In other studies, L¨ otsch et al. examined 251 unrelated
individuals with cancer and pain [58]. The study subjects
were homozygous carriers of the GCH1 variant, and it was
noted that the time between cancer diagnosis and the need
foropioidtherapyinitiationwaslongerthaninheterogenous
individuals. Hence, suggesting reduced GCH1 upregulation
delays the need for opioid initiation in cancer treatment.
Two studies, however, failed to corroborate the GCH1
pain protective haplotype and decreased pain ratings.
Lazarev et al. [59] examined genetic variations in the GCH1
gene in two SNPs (rs8007267 G > A and rs 3783641 A > T)
and concluded that even with a large sample size of patients
(236 Caucasians), signiﬁcant pain patterns based on the
GCH1 genotype could not be distinguished. The researchers
concluded that the visceral pain pathway of pancreatitis
may be diﬀerent from that of neuropathic pain [59]. In
another study, Kim and Dionne [60] failed to replicate the
GCH1 gene variant is linked to lower pain response. This
study examined healthy individuals with surgical removal
of impacted molars. Their inconsistencies, however, may
be related to their mixed ethnic sample, which induced
population stratiﬁcation and made it diﬃcult to identify the
pain phenotype [60].
3. Implications for Future
Research andPractice
More work is needed to clearly deﬁne chronic pain pheno-
types among individuals with SCD. Diﬀerences among vary-
ing phenotypic presentations also need to be studied. This
need for more clinical research regarding SCD, chronic pain,
and healthcare provision [37, 38] will help with improving
the understanding of the chronic pain phenomenon, oﬀer
culturally appropriate interventions, and improve care for
those who are vulnerable to disparate care. Research is
needed to more clearly deﬁne chronic pain for those with
SCD and guide the development of culturally and ethnically
appropriate interventions to minimize complications and
improve quality of life. There is the need and promise to
personalize care based on individual genetic predisposition.
Research studies pertaining to chronic SCD pain should
include genomics as a variable in a multidisciplinary
approach. These studies should be conducted to identify
relationships between pain reports and genomic markers,
using appropriate designs such as candidate gene association
studies. By using the candidate gene approach, researchers
can have a focused view of genomic regions of interest.
Hence, instead of ﬁshing widely and possibly blindly in the
human genome, correlation procedures may be applied to
speciﬁcally identiﬁed SNPs in candidate genes associated
with pain. By using translational research designs, bench
ﬁndings may have clinical applicability in identifying factors
that aﬀect the heterogeneity of pain.
The challenges of prior research with this population,
such as small sample sizes and lack of power, might be
minimized with a multisite approach. In addition to quan-
titative inquiry, qualitative inquiry will capture subjective
perspective, and advance our knowledge of this complex and
debilitating condition. The blending of genomic data with
chronic pain phenomena could enrich our interventions for
people with SCD and chronic pain.
The functional impact of polymorphisms might identify
one reason for variability or heterogeneity of pain phenotype
in SCD. By using a holistic approach inclusive of genomics,
researchers may better identify underlying mechanisms
of chronic pain to ultimately inﬂuence clinical treatment
decisions. Additionally, personalized healthcare will improve
when we better understand the genetic component to pain
and how this aﬀects symptoms.
4. Conclusion
SCD is a complex and challenging condition accompanied
by serious problems with chronic pain management. Pain
protective genes have been implicated in chronic pain
syndromes and could be applied to further study SCD. By
using a candidate gene approach, researchers can evaluate
interactions among many SNPs and the risk for SCD
complications such as chronic pain. For example, analyzing
individuals with SCD for mutations in GCH1 may help to
explain the variability in pain ratings. Nurse scientists in a
multidisciplinary team can contribute by developing inno-
vative models that use multiple factors to predict individual’s
risks for disease development, symptom manifestation, and
response to interventions. These important contributions
can assist in early treatment of chronic pain and minimize
sequela complications.
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